Enliven Therapeutics Stock Market Value
| ELVN Stock | 24.88 0.34 1.39% |
| Symbol | Enliven |
Enliven Therapeutics Price To Book Ratio
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enliven Therapeutics. If investors know Enliven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enliven Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.89) | Return On Assets (0.21) | Return On Equity (0.31) |
The market value of Enliven Therapeutics is measured differently than its book value, which is the value of Enliven that is recorded on the company's balance sheet. Investors also form their own opinion of Enliven Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Enliven Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enliven Therapeutics' market value can be influenced by many factors that don't directly affect Enliven Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enliven Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enliven Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enliven Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Enliven Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Enliven Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Enliven Therapeutics.
| 10/26/2024 |
| 11/25/2024 |
If you would invest 0.00 in Enliven Therapeutics on October 26, 2024 and sell it all today you would earn a total of 0.00 from holding Enliven Therapeutics or generate 0.0% return on investment in Enliven Therapeutics over 30 days. Enliven Therapeutics is related to or competes with Capricor Therapeutics, Soleno Therapeutics, Bio Path, Moleculin Biotech, Crinetics Pharmaceuticals, Assembly Biosciences, and Instil Bio. Enliven Therapeutics is entity of United States More
Enliven Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Enliven Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Enliven Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.2 | |||
| Information Ratio | 0.0032 | |||
| Maximum Drawdown | 12.96 | |||
| Value At Risk | (4.07) | |||
| Potential Upside | 5.84 |
Enliven Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Enliven Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Enliven Therapeutics' standard deviation. In reality, there are many statistical measures that can use Enliven Therapeutics historical prices to predict the future Enliven Therapeutics' volatility.| Risk Adjusted Performance | 0.0473 | |||
| Jensen Alpha | 0.0021 | |||
| Total Risk Alpha | (0.29) | |||
| Sortino Ratio | 0.0038 | |||
| Treynor Ratio | 0.1228 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enliven Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enliven Therapeutics Backtested Returns
As of now, Enliven Stock is very steady. Enliven Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0699, which denotes the company had a 0.0699% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for Enliven Therapeutics, which you can use to evaluate the volatility of the firm. Please confirm Enliven Therapeutics' Coefficient Of Variation of 1910.48, downside deviation of 2.2, and Mean Deviation of 1.87 to check if the risk estimate we provide is consistent with the expected return of 0.19%. Enliven Therapeutics has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.05, which means a somewhat significant risk relative to the market. Enliven Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Enliven Therapeutics is expected to follow. Enliven Therapeutics right now shows a risk of 2.7%. Please confirm Enliven Therapeutics downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Enliven Therapeutics will be following its price patterns.
Auto-correlation | 0.28 |
Poor predictability
Enliven Therapeutics has poor predictability. Overlapping area represents the amount of predictability between Enliven Therapeutics time series from 26th of October 2024 to 10th of November 2024 and 10th of November 2024 to 25th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Enliven Therapeutics price movement. The serial correlation of 0.28 indicates that nearly 28.0% of current Enliven Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.28 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 1.0 |
Enliven Therapeutics lagged returns against current returns
Autocorrelation, which is Enliven Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Enliven Therapeutics' stock expected returns. We can calculate the autocorrelation of Enliven Therapeutics returns to help us make a trade decision. For example, suppose you find that Enliven Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Enliven Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Enliven Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Enliven Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Enliven Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Enliven Therapeutics Lagged Returns
When evaluating Enliven Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Enliven Therapeutics stock have on its future price. Enliven Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Enliven Therapeutics autocorrelation shows the relationship between Enliven Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Enliven Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Enliven Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enliven Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enliven Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Enliven Stock
| 0.84 | VCNX | Vaccinex | PairCorr |
| 0.72 | GMAB | Genmab AS | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.61 | LEGN | Legend Biotech Corp | PairCorr |
| 0.59 | KRYS | Krystal Biotech | PairCorr |
The ability to find closely correlated positions to Enliven Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enliven Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enliven Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enliven Therapeutics to buy it.
The correlation of Enliven Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enliven Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enliven Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enliven Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Enliven Therapeutics Correlation, Enliven Therapeutics Volatility and Enliven Therapeutics Alpha and Beta module to complement your research on Enliven Therapeutics. To learn how to invest in Enliven Stock, please use our How to Invest in Enliven Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Enliven Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.